- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- flow cytometry, laboratory biomarker analysis, Data Collection
- Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 12,225
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Agitation in Dementia, Including Alzheimer's Disease
- Interventions
- ITI-007, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 26
- States / cities
- Sun City, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 23 more
- Conditions
- Traumatic Brain Injury, Posttraumatic Stress Disorders, Trauma, Combat Disorders, Pain
- Interventions
- TMRDU
- Device
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Camp Pendleton, California • Tampa, Florida • Fort Knox, Kentucky
- Conditions
- Newly Diagnosed Multiple Myeloma
- Interventions
- Ixazomib, Lenalidomide
- Drug
- Lead sponsor
- Oncotherapeutics
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- West Hollywood, California
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Lansoprazole microgranules suspension, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 1 Month to 11 Months
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Park Ridge, Illinois • Shreveport, Louisiana + 6 more
- Conditions
- Meningitis, Cryptococcal, HIV Infections
- Interventions
- Fluconazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 13 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Tampa, Florida + 10 more
- Conditions
- NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Interventions
- IDP-023, Rituximab, Daratumumab, Interleukin-2, Cyclophosphamide, Fludarabine, Mesna, Isatuximab
- Drug
- Lead sponsor
- Indapta Therapeutics, INC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Lake Mary, Florida • Atlanta, Georgia + 9 more
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Trastuzumab Emtansine
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, Waldenström Macroglobulinemia
- Interventions
- alvocidib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Down Syndrome, Speech and Language Disorder, Speech Disorders in Children, Speech Intelligibility, Speech Sound Disorder
- Interventions
- AAC Generative Language Intervention, Standard of Care / Business as Usual
- Behavioral
- Lead sponsor
- University of Central Florida
- Other
- Eligibility
- 3 Years to 4 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Albuquerque, New Mexico
- Conditions
- Schizophrenia
- Interventions
- Clinical Learning Study smartphone app (i.e., the study app)
- Device
- Lead sponsor
- Click Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 7
- States / cities
- Anaheim, California • Torrance, California • Hialeah, Florida + 4 more
- Conditions
- Circadian Rhythm Sleep Disorder, Jet Lag Type
- Interventions
- Bright Light, Bright Light + Exercise + Melatonin, Control
- Behavioral
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Olorinab, Placebo
- Drug
- Lead sponsor
- Arena Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 60 more
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Glaucoma
- Interventions
- Trabeculectomy, Ex-PRESS mini shunt
- Procedure · Device
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 7
- States / cities
- San Francisco, California • Gainesville, Florida • St Louis, Missouri + 4 more
- Conditions
- Alzheimer's Disease
- Interventions
- CAD106, Placebo, Alum, MF59
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Up to 85 Years
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 2 more
- Conditions
- Hepatitis C
- Interventions
- GI-5005
- Biological
- Lead sponsor
- GlobeImmune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 5
- States / cities
- Pasadena, California • Denver, Colorado • Miami, Florida + 2 more
- Conditions
- Cough Reflex Sensitivity
- Interventions
- diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo, diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan, dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo, dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa, placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan, placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Marfan Syndrome
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 10 Years to 19 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Acute Kidney Injury
- Interventions
- THR-184, Placebo
- Drug
- Lead sponsor
- Thrasos Innovation, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stanford, California + 26 more
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- NCX 470 0.065% (initial phase of trial), Latanoprost 0.005% (initial phase of trial), NCX 470 0.1% (initial phase of trial), NCX 470 0.1% (remainder of trial), Latanoprost 0.005% (remainder of trial)
- Drug
- Lead sponsor
- Nicox Ophthalmics, Inc.
- Industry
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 691 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Breast Cancer, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cancer
- Interventions
- NIS793, PDR001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • Salt Lake City, Utah
- Conditions
- Cerebral Vasospasm
- Interventions
- Nicardipine, Verapamil, Nicardipine + Verapamil + Nitroglycerin
- Drug
- Lead sponsor
- Peng Roc Chen, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Manhasset, New York • Winston-Salem, North Carolina + 2 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab, Placebo, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine, Surgery
- Drug · Other · Procedure
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 825 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Duarte, California • Orange, California + 25 more